Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas
| Autor: | Michael Howell, Nathan Bahary, A. James Moser, Simul Parikh, Dwight E. Heron, Steven A. Burton, Herbert J. Zeh, Jean-Claude M. Rwigema, Annette E. Quinn |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Adenocarcinoma Radiosurgery Pancreatic cancer medicine Humans External beam radiotherapy Survival rate Aged Neoplasm Staging Aged 80 and over business.industry Middle Aged medicine.disease Pancreatic Neoplasms Survival Rate medicine.anatomical_structure Treatment Outcome Oncology Toxicity Feasibility Studies Female Radiology Neoplasm Recurrence Local business Pancreas Adjuvant Follow-Up Studies |
| Zdroj: | American journal of clinical oncology. 34(1) |
| ISSN: | 1537-453X |
| Popis: | OBJECTIVES The aim of the study was to assess the feasibility and safety of stereotactic body radiotherapy (SBRT) in patients with advanced pancreatic adenocarcinoma. METHODS We reviewed outcomes of 71 patients treated with SBRT for pancreatic cancer between July 2004 and January 2009. Forty patients (56%) had locally unresectable disease, 11 patients (16%) had local recurrence following surgical resection, 8 patients (11%) had metastatic disease, and 12 patients (17%) received adjuvant SBRT for positive margins. The median dose was 24 Gy (18-25 Gy), given in a single-fraction SBRT (n = 67) or fractionated SBRT (n = 4). Kaplan-Meyer survival analyses were used to estimate freedom from local progression (FFLP) and overall survival (OS) rates. RESULTS The median follow-up among surviving patients was 12.7 months (4-26 months). The median tumor volume was 17 mL (5.1-249 mL). The overall FFLP rates at 6 months/1 year were 71.7%/48.5%, respectively. Among those with macroscopic disease, FFLP was achieved in 77.3% of patients with tumor size |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|